A successful case of dupilumab treatment for severe uremic pruritus

Jonathan I. Silverberg; Joaquin Brieva

doi:10.1016/j.jdcr.2019.01.024

A successful case of dupilumab treatment for severe uremic pruritus

Jonathan I. Silverberg^*, Joaquin Brieva

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Original language	English (US)
Pages (from-to)	339-341
Number of pages	3
Journal	JAAD Case Reports
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/j.jdcr.2019.01.024
State	Published - Apr 2019

Keywords

itch
scratch
treatment
uremic pruritus

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jdcr.2019.01.024

Cite this

@article{3f0314455e53422fa550b6994e3ad6a0,

title = "A successful case of dupilumab treatment for severe uremic pruritus",

keywords = "itch, scratch, treatment, uremic pruritus",

author = "Silverberg, {Jonathan I.} and Joaquin Brieva",

note = "Funding Information: Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose. Funding sources: None. Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose.",

year = "2019",

month = apr,

doi = "10.1016/j.jdcr.2019.01.024",

language = "English (US)",

volume = "5",

pages = "339--341",

journal = "JAAD Case Reports",

issn = "2352-5126",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - A successful case of dupilumab treatment for severe uremic pruritus

AU - Silverberg, Jonathan I.

AU - Brieva, Joaquin

N1 - Funding Information: Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose. Funding sources: None. Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose.

PY - 2019/4

Y1 - 2019/4

KW - itch

KW - scratch

KW - treatment

KW - uremic pruritus

UR - http://www.scopus.com/inward/record.url?scp=85063743182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063743182&partnerID=8YFLogxK

U2 - 10.1016/j.jdcr.2019.01.024

DO - 10.1016/j.jdcr.2019.01.024

M3 - Article

C2 - 30993160

AN - SCOPUS:85063743182

SN - 2352-5126

VL - 5

SP - 339

EP - 341

JO - JAAD Case Reports

JF - JAAD Case Reports

IS - 4

ER -

A successful case of dupilumab treatment for severe uremic pruritus

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this